Private equity investment as a divining rod for market failure: Policy responses to harmful physician practice acquisitions Erin C. Fuse Brown, Loren Adler, Erin Duffy, Paul B. Ginsburg, Mark Hall, and Samuel Valdez Tuesday, October 5, 2021
A framework for categorizing and analyzing prescription drug pricing reform options Rachel Sachs, Loren Adler, and Paul B. Ginsburg Tuesday, August 31, 2021
Government regulated or negotiated drug prices: Key design considerations Paul B. Ginsburg and Steven M. Lieberman Monday, August 30, 2021
2021 Apr 9 Past Event Wall Street Comes to Washington health care roundtable 2:00 PM - 3:45 PM EDT Online Only
Medicare advanced imaging payment: Dysfunctional policy making Bruce Steinwald, Paul B. Ginsburg, Caitlin Brandt, and Sobin Lee Wednesday, March 31, 2021
Medicare payment for physician-administered (Part B) drugs Paul B. Ginsburg and Steven M. Lieberman Wednesday, February 10, 2021
Understanding the No Surprises Act Loren Adler, Matthew Fiedler, Paul B. Ginsburg, Mark Hall, Benedic Ippolito, and Erin Trish Thursday, February 4, 2021
Balancing lower U.S. prescription drug prices and innovation – Part 2 Steven M. Lieberman, Paul B. Ginsburg, and Kavita Patel Wednesday, November 25, 2020
Balancing lower U.S. prescription drug prices and innovation – Part 1 Steven M. Lieberman, Paul B. Ginsburg, and Kavita Patel Tuesday, November 24, 2020
